Monitor for effectiveness of the S-4 registration statement, Nasdaq listing approval, and satisfaction of closing conditions. The merger is expected to close in Q3 2026, but completion risk exists given multiple conditions. The CVRs attached to Galera's legacy assets may provide upside but are contingent and could expire worthless.
Price Chart
Executive Summary
Gazelle Parent, Inc. filed Amendment No. 4 to the S-4 registration statement for its proposed reverse merger with Obsidian Therapeutics and Galera Therapeutics. The merger values Obsidian at $413.5 million and Galera at $10 million, with a concurrent $350 million PIPE financing. Post-closing, Galera stockholders will own approximately 1.29% of the combined company and receive CVRs for legacy assets, while Obsidian and PIPE investors will own the majority. The combined company (renamed Obsidian Therapeutics) is expected to trade on Nasdaq under OBX.
Key Facts
- Merger agreement signed April 14, 2026; Obsidian and Galera become wholly owned subsidiaries of Gazelle Parent.
- Concurrent PIPE financing of $350 million from Galera Series C preferred stock issuance.
- Galera stockholders estimated to receive 781,649 Parent shares (0.7515 exchange ratio after 1:200 reverse split) plus CVRs for tilarginine and supportive-care products.
- Obsidian stockholders estimated to receive 31,647,468 Parent shares (0.1375 exchange ratio) based on $413.5 million valuation.
- Post-closing ownership (illustrative): Galera ~1.29%, Obsidian ~53.46%, PIPE investors ~45.25%.
- Parent common stock expected to list on Nasdaq under ticker OBX; condition to closing.
- Support agreements from Galera (51.1%) and Obsidian (62.8%) stockholders; 180-day lock-up for >50% of Obsidian shares.
- Termination fees: Obsidian pays $1.25 million to Galera in certain scenarios; Galera pays $0.75 million to Obsidian.
- Galera Board received fairness opinion from Lucid Capital Markets.
- Closing expected in Q3 2026, subject to Nasdaq listing, SEC effectiveness, and PIPE funding.
Financial Impact
Galera stockholders receive ~1.29% of combined company plus CVRs; Obsidian and PIPE investors receive substantial majority. Combined company gains ~$350 million in cash from PIPE.
Risk Factors
- Failure to satisfy closing conditions, including Nasdaq listing approval and receipt of $350 million PIPE proceeds.
- Galera stockholders may receive no value from CVRs if tilarginine or supportive-care assets are not monetized.
- Stockholder litigation could delay or block the merger.
- Combined company will require additional capital post-merger despite $350 million infusion.
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-4/A Filing (Primary) | 0001193125-26-293383 |
| Document: d117787dex51.htm | 0001193125-26-293383 |
| Document: d117787dex81.htm | 0001193125-26-293383 |
| Document: d117787dex231.htm | 0001193125-26-293383 |
| Document: d117787dex232.htm | 0001193125-26-293383 |
| Document: 0001193125-26-293383-index-headers.html | 0001193125-26-293383 |
| Document: 0001193125-26-293383-index.html | 0001193125-26-293383 |
| Document: 0001193125-26-293383.txt | 0001193125-26-293383 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 21d ago | SC 13G | $13.22 | awaiting T+20 | — | $14.17 (+7.19%) |
Sep 10, 2026 6w ago | EFFECT | $17.16 $12.24 | ▼ −28.67% | ▼ −30.80% | $14.17 (−17.42%) |
Aug 3, 2026 12w ago | 3 | $34.00 $17.04 | ▼ −49.88% | ▼ −48.64% | $14.17 (−58.32%) |
Aug 3, 2026 12w ago | 3 | $34.00 $17.04 | ▼ −49.88% | ▼ −48.64% | $14.17 (−58.32%) |
Aug 3, 2026 12w ago | 3 | $34.00 $17.04 | ▼ −49.88% | ▼ −48.64% | $14.17 (−58.32%) |
Aug 3, 2026 12w ago | 3 | $34.00 $17.04 | ▼ −49.88% | ▼ −48.64% | $14.17 (−58.32%) |
Aug 3, 2026 12w ago | 3 | $34.00 $17.04 | ▼ −49.88% | ▼ −48.64% | $14.17 (−58.32%) |
Aug 3, 2026 12w ago | 3 | $34.00 $17.04 | ▼ −49.88% | ▼ −48.64% | $14.17 (−58.32%) |
Aug 3, 2026 12w ago | 8-K | $34.00 $17.04 | ▲ +49.88% | ▲ +48.64% | $14.17 (+58.32%) |
Jul 6, 2026 16w ago | EFFECT | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers